BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7539318)

  • 1. Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD.
    Carella AM; Pollicardo N; Pungolino E; Frassoni F; Giordano D; Bruni R; Spriano M; Rossi E
    Leuk Lymphoma; 1995; 15 Suppl 1():59-61. PubMed ID: 7539318
    [No Abstract]   [Full Text] [Related]  

  • 2. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy.
    Carella AM; Prencipe E; Pungolino E; Lerma E; Frassoni F; Rossi E; Giordano D; Occhini D; Gatti AM; Bruni R; Spriano M; Nati S; Pierluigi D; Congiu M; Vimercati R; Ravetti JL; Federico M
    Leuk Lymphoma; 1996 Mar; 21(1-2):63-70. PubMed ID: 8907271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation.
    Salloum E; Tanoue LT; Wackers FJ; Zelterman D; Hu GL; Cooper DL
    Cancer Invest; 1999; 17(3):171-80. PubMed ID: 10099655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
    Carella AM; Carlier P; Congiu A; Occhini D; Nati S; Santini G; Pierluigi D; Giordano D; Bacigalupo A; Damasio E
    Bone Marrow Transplant; 1991 Aug; 8(2):99-103. PubMed ID: 1718517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].
    Gisselbrecht C; Lepage E; Brice P; Trédaniel J; Gerota I
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):131-4. PubMed ID: 2455276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
    Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
    [No Abstract]   [Full Text] [Related]  

  • 14. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
    Santoro A; Bonfante V; Bonadonna G
    Ann Intern Med; 1982 Feb; 96(2):139-43. PubMed ID: 6174060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience.
    Bonadonna G; Santoro A; Gianni AM; Viviani S; Siena S; Bregni M; Zucali R; Lombardi F; Bonfante V; Gianni L
    Ann Oncol; 1991 Jan; 2 Suppl 1():9-16. PubMed ID: 1710489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.